This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
Effect of 2 years of high-dose growth hormone therapy on cognitive and psychosocial development in short children born small for gestational age.
OBJECTIVE AND DESIGN Children born small for gestational age ( SGA ) are not only at risk for short stature , but also for neurodevelopmental and behavioral problems . In this study , we analyzed the effects of high-dose GH therapy on cognitive development and psychosocial functioning in 34 prepubertal ( 3 - 8 years ) short SGA children , equally r and omized into a GH-treated group ( TRG ) and an untreated group ( UTRG ) . METHODS At start and after 2 years , children underwent st and ardized tests measuring the intellectual abilities ( Wechsler Preschool and Primary Scale of Intelligence-Revised , or Wechsler Intelligence Scale for Children-Revised ) ; their parents completed a st and ardized question naire evaluating psychosocial functioning ( Child Behavior Checklist ; CBCL ) . RESULTS At start , total IQ scores were significantly ( P < 0.05 ) lower in the SGA group than in the general population : 32 % of the SGA patients had scores below 85 . After 2 years , IQ scores remained unchanged in the TRG , but increased significantly ( P < 0.05 ) in the UTRG . After exclusion of children with developmental problems , however , no significant changes in IQ scores occurred in the UTRG as well as the TRG . At baseline , 24 % ( 8/34 ) children had problematic CBCL total problems scores , equally distributed among the two groups ; no significant changes in the different subscale scores occurred after 2 years . CONCLUSION No beneficial effect of 2 years of GH therapy on cognitive and behavioral profile could be observed in a cohort of rather young short SGA children presenting a variable degree of developmental delay and behavioral problems . Subsequent follow-up could reveal potential long-term effects of GH therapy on development and behavior
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .